Journal of Biomedical Science and Engineering

Volume 4, Issue 9 (September 2011)

ISSN Print: 1937-6871   ISSN Online: 1937-688X

Google-based Impact Factor: 0.66  Citations  h5-index & Ranking

IL13-induced lung fibrosis in meconium aspiration

HTML  Download Download as PDF (Size: 908KB)  PP. 609-619  
DOI: 10.4236/jbise.2011.49077    3,965 Downloads   7,571 Views  Citations

Affiliation(s)

.

ABSTRACT

We demonstrated previously that inflammatory cy-tokines TNF, IL-1, IL-6 and IL-8 are signifi-cantly expressed in meconium-instilled lungs. Capto-pril was a strong inhibitor of meconium-induced lung injury, inflammation and apoptosis and reduces lung alveolar and airway epithelial cell damage. Presently we demonstrate that IL-13 expression in the me-conium aspiration syndrome (MAS). IL-13 was maximally expressed 8 hrs after meconium instilla-tion. It was previously described that IL-13 plays a major role in degradation of airway epithelial cells and inducing of lung fibrosis by activating collagen production that is a major point in identification of lung fibrosis. We also showed that Captopril treat-ment significantly inhibits IL-13 expression in the lungs. We believe it reduces meconium-induced lung injury and has a therapeutic effect on histological and biochemical functions of the lungs and possibly pulmonary fibrosis. Captopril treatment significantly reduced the number of neuprophils and macrophages which express IL13 and levels of other inflammatory cytokines after meconium instillation. Selective neu-tralization of IL-13 ameliorated lung injury, airway hyper responsiveness, eosinophil recruitment and mucus overproduction.

Share and Cite:

Zagariya, A. , Navale, S. , Zagariya, O. , McClain, K. and Vidyasagar, D. (2011) IL13-induced lung fibrosis in meconium aspiration. Journal of Biomedical Science and Engineering, 4, 609-619. doi: 10.4236/jbise.2011.49077.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.